2010 | 2009 | 2008 | 2007 | 2006 | 2005
Keyword Search
 
Date Title
12/08/09Printer Friendly VersionAllos Therapeutics' FOLOTYN(TM) Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Lymphoma
12/07/09Printer Friendly VersionAllos Therapeutics' FOLOTYN(TM) Demonstrates Activity in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma Treated with Stem Cell Transplant
12/05/09Printer Friendly VersionAllos Therapeutics Reports New Analyses of Data from Pivotal PROPEL Trial of FOLOTYN(TM) at 51st ASH Annual Meeting
12/04/09Printer Friendly VersionAllos Therapeutics Announces an Agreement with Idis for a Named Patient Program for FOLOTYN(TM) (pralatrexate injection)
12/03/09Printer Friendly VersionAllos Therapeutics to Launch Global Registry for Patients with Peripheral T-Cell Lymphoma at the American Society of Hematology Annual Meeting
11/30/09Printer Friendly VersionAllos Therapeutics Announces Issuance of U.S. Patent for FOLOTYN
11/11/09Printer Friendly VersionAllos Therapeutics Announces New Data on FOLOTYN(TM) to be Presented at the American Society of Hematology Meeting
11/10/09Printer Friendly VersionAllos Therapeutics to Present at Upcoming Conferences in November
11/03/09Printer Friendly VersionAllos Therapeutics Reports Third Quarter 2009 Financial Results
10/26/09Printer Friendly VersionAllos Therapeutics to Report Third Quarter 2009 Results on November 3, 2009
10/13/09Printer Friendly VersionAllos Therapeutics Announces Closing of Public Offering
10/07/09Printer Friendly VersionAllos Therapeutics Announces Pricing of Public Offering of Common Stock
10/05/09Printer Friendly VersionAllos Therapeutics Announces Proposed Public Offering of Common Stock
10/05/09Printer Friendly VersionAllos Therapeutics Announces U.S. Availability of FOLOTYN(TM) (pralatrexate injection) for Relapsed or Refractory Peripheral T-Cell Lymphoma
09/25/09Printer Friendly VersionAllos Therapeutics' FOLOTYN(TM) First and Only FDA-Approved Therapy for Relapsed or Refractory Peripheral T-cell Lymphoma
09/02/09Printer Friendly VersionAllos Therapeutics Announces FDA Advisory Committee Recommends Accelerated Approval of FOLOTYN(TM) (pralatrexate) for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
09/01/09Printer Friendly VersionAllos Therapeutics to Hold Post Advisory Committee Conference Call
08/10/09Printer Friendly VersionAllos Therapeutics Announces FDA Advisory Committee to Review Pralatrexate for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
08/04/09Printer Friendly VersionAllos Therapeutics Reports Second Quarter 2009 Financial Results
07/23/09Printer Friendly VersionAllos Therapeutics Launches Peripheral T-Cell Lymphoma Website
07/22/09Printer Friendly VersionAllos Therapeutics to Report Second Quarter 2009 Results on August 4, 2009
07/07/09Printer Friendly VersionAllos Therapeutics Completes Enrollment in Randomized Phase 2b Trial of Pralatrexate in Patients with Advanced Non-Small Cell Lung Cancer
06/03/09Printer Friendly VersionAllos Therapeutics to Present at the 8th Annual Needham Life Sciences Conference
05/30/09Printer Friendly VersionAllos Therapeutics Reports Updated Data from Pivotal Phase 2 PROPEL Study of Pralatrexate at 45th ASCO Annual Meeting
05/26/09Printer Friendly VersionAllos Therapeutics Announces FDA Accepts Pralatrexate NDA for Filing and Grants the Application Priority Review Status
05/14/09Printer Friendly VersionAllos Therapeutics Announces Updated Data from Pivotal Phase 2 PROPEL Study of Pralatrexate to be Presented at ASCO 2009
05/12/09Printer Friendly VersionAllos Therapeutics to Present at the Eighth Annual JMP Securities Research Conference
05/05/09Printer Friendly VersionAllos Therapeutics Reports First Quarter 2009 Financial Results
04/28/09Printer Friendly VersionAllos Therapeutics to Report First Quarter 2009 Results on May 5, 2009
04/19/09Printer Friendly VersionAllos Therapeutics' Pralatrexate Demonstrates Anticancer Activity in Multiple Cancer Cell Lines
04/15/09Printer Friendly VersionAllos Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2009
04/03/09Printer Friendly VersionAllos Therapeutics Announces Closing of Common Stock Offering
03/31/09Printer Friendly VersionAllos Therapeutics Announces Pricing of Common Stock Offering
03/25/09Printer Friendly VersionAllos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
03/24/09Printer Friendly VersionAllos Therapeutics Appoints David M. Stout to Its Board of Directors
03/17/09Printer Friendly VersionAllos Therapeutics' Pralatrexate Granted Orphan Medicinal Product Designation for the Treatment of Bladder Cancer by the European Commission
03/03/09Printer Friendly VersionAllos Therapeutics Reports 2008 Results
02/26/09Printer Friendly VersionAllos Therapeutics to Report 2008 Results on March 3, 2009
02/03/09Printer Friendly VersionAllos Therapeutics Announces Final Results from Pivotal PROPEL Trial of Pralatrexate in Patients with Peripheral T-cell Lymphoma
02/02/09Printer Friendly VersionAllos Therapeutics to Present at the 2009 BIO CEO & Investor Conference
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Allos Therapeutics, Inc. has a news release. Just enter your e-mail address and click Submit.